Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)-Reference-Cited by-同舟云学术

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

Published:2019-07-22 Issue:1 Volume:17 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Ascierto Paolo A.^ORCID,Agarwala Sanjiv S.,Botti Gerardo,Budillon Alfredo,Davies Michael A.,Dummer Reinhard,Ernstoff Marc,Ferrone Soldano,Formenti Silvia,Gajewski Thomas F.,Garbe Claus,Hamid Omid,Lo Roger S.,Luke Jason J.,Michielin Oliver,Palmieri Giuseppe,Zitvogel Laurence,Marincola Francesco M.,Masucci Giuseppe,Caracò Corrado,Thurin Magdalena,Puzanov Igor

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12967-019-1979-z.pdf

Reference61 articles.

1. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–55.

2. Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, et al. E3611—a randomized phase II study of ipilimumab at 3 or 10 mg/kg alone or in combination with high-dose interferon-α2b in advanced melanoma. Clin Cancer Res. 2018. https://doi.org/10.1158/1078-0432.ccr-18-2258 .

3. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.

4. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.

5. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813–23.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015–2018 in Greece. The ‘SUMMER’ study: a retrospective multicenter chart review project;Melanoma Research;2023-12-13

2. Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma;Frontiers in Oncology;2021-07-09

3. DNA Damage Repair Gene Set as a Potential Biomarker for Stratifying Patients with High Tumor Mutational Burden;Biology;2021-06-14

4. Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies;Frontiers in Oncology;2021-05-28

5. Anticancer Activity of Two Novel Hydroxylated Biphenyl Compounds toward Malignant Melanoma Cells;International Journal of Molecular Sciences;2021-05-26